Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Research output: Contribution to journalArticlepeer-review


  • Anne-laure Vallier
  • Shrushma Loi
  • Karen Mcadam
  • Luke Hughes-davies
  • Donna Howe
  • Kerry Raynes
  • Helen B Higgins
  • Maggie Wilcox
  • Chris Plummer
  • Betania Mahler-araujo
  • Elena Provenzano
  • Anita Chhabra
  • Sophie Gasson
  • Claire Balmer
  • Jean E Abraham
  • Carlos Caldas
  • Peter Hall
  • Bethany Shinkins
  • Claire Hulme
  • Andrew M Wardley
  • David A Cameron
  • Janet A Dunn

External organisations

  • University of Cambridge
  • Cambridge University Hospitals NHS Foundation Trust
  • NIHR Cambridge Biomedical Research Centre
  • University of Warwick
  • University of Birmingham
  • National Cancer Research Institute Consumer Liaison Group (NCRI CLG); Independent Cancer Patients Voice (ICPV); London UK
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
  • University of Edinburgh
  • Institute of Health Economics
  • Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.
  • University of Manchester
  • Newcastle University
  • The Christie NHS Foundation Trust
  • University of Leeds
  • University of Exeter


Original languageEnglish
Pages (from-to)1-190
JournalHealth Technology Assessment
Issue number40
Publication statusPublished - 2 Sep 2020

Sustainable Development Goals